MannKind Corp. (MNKD)
-NasdaqGM 6.85 
0.62(9.95%) May 23, 4:00PM EDT|After Hours
:
6.80 0.05 (0.73%) May 23, 7:59PM EDT
| Prev Close: | 6.23 |
|---|
| Open: | 6.46 |
|---|
| Bid: | 6.73 x 300 |
|---|
| Ask: | 6.80 x 400 |
|---|
| 1y Target Est: | 6.14 |
|---|
| Beta: | 1.08 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 6.23 - 6.99 |
|---|
| 52wk Range: | 1.65 - 6.99 |
|---|
| Volume: | 19,997,543 |
|---|
| Avg Vol (3m): | 6,192,800 |
|---|
| Market Cap: | 1.92B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.80 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
Headlines
- Most active Nasdaq-traded stocksAP(Thu, May 23)
- MannKind's Run to Gloryat Motley Fool(Thu, May 23)
- [video] Options Activity Ahead of Pandora Earningsat CNBC(Thu, May 23)
- Commit To Buy MannKind Corp At $2.50, Earn 28%at TheStreet(Thu, May 23)
- Arena Buyout More 'Highly Probable' Than MannKindat Seeking Alpha(Thu, May 23)
- [video] Nasdaq Check: Tech Stocks Recoverat CNBC(Thu, May 23)
- What's behind put surge in MannKindoptionMONSTER(Thu, May 23)
- The Coming Diabetes Warsat Motley Fool(Thu, May 23)
- Largest option buying in equities so faroptionMONSTER(Thu, May 23)
- 2 Biotechs to Avoid, 1 to Buyat Motley Fool(Thu, May 23)
- MannKind's Afrezza And The Oramed Threatat Seeking Alpha(Thu, May 23)
- American Capital Adds to Global Investment Team and 2 More Heavily Traded Stocks to Followat Wall St. Cheat Sheet(Wed, May 22)
- MannKind shares leap as web site says firm is a ripe takeover targetat MarketWatch(Wed, May 22)
- MannKind attracts huge call strategyoptionMONSTER(Wed, May 22)
- Largest option buying in equities so faroptionMONSTER(Wed, May 22)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 49,906.75 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.51 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.14 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 0.06 |
|---|
Business Summary
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.
View More